chartexchange

PharmaLogic Signs Lantheus CDMO Deal With Long-Term Supply Agreement

Securities.io | Nov 9, 2026 6:34 PM EST

PharmaLogic Holdings Corp. announced the agreement on November 9, 2026, saying it had entered into a definitive agreement to acquire Lantheus Holdings’ contract development and manufacturing organization (CDMO) business and its Springfield, New Jersey, manufacturing facility. Financial terms were not disclosed. The transaction also includes a long-term supply agreement under which Agilera, PharmaLogic’s therapeutic CDMO franchise, will manufacture lutetium Lu 177 dotatate for Lantheus. The…

Read original article